More Depressing News For Biovail: Decision On New Wellbutrin Formula Six Months Away
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency has designated Biovail’s complete response to a “not approvable” letter as a class 2 review, giving application an April 23, 2008, action date, as opposed to a class 1 review, which would take only two months.